SEC Form 4 · accession 0000885590-15-000026
Bausch Health Companies Inc. · BHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laizer Kornwasser
Officer — EVP, Company Group Chairman
Period of report
Apr 17, 2015
Accepted (ET)
Apr 21, 2015 · 5:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885590
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, no par valueF2,F1 | Apr 17, 2015 | M | 45,000 | $0.00 | A | 123,377 | D | |
| Common Stock, no par valueF3 | Apr 17, 2015 | F | 23,337 | $0.00 | D | 100,040 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F1 | — | Apr 17, 2015 | M | 45,000 | D | — | — | Common Stock | 45,000 | 0 | D |
Explanation of responses
- F1Each performance-based Restricted Share Unit ("RSU") represents a contingent right to receive between zero and three common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
- F2These RSUs were initially eligible to vest based on total shareholder return (TSR) between a price of $63.86 starting on February 1, 2013 and the average stock price for the 20 trading days starting on each measurement dates: 25% on November 1, 2015, 50% on February 1, 2016 and 25% on May 1, 2016, contingent on TSR performance between 10% and 30% into between one and three Common Shares of common stock, respectively, with early vesting possible at higher TSR levels. These performance-based RSUs have now vested in full.
- F3This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of performance-based RSUs.